Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2025 | $17.50 | Underweight → Overweight | Morgan Stanley |
| 7/29/2025 | $14.00 | Sell → Neutral | Citigroup |
| 3/11/2025 | $19.00 → $17.00 | Equal-Weight → Underweight | Morgan Stanley |
| 1/31/2025 | $18.00 → $15.00 | Neutral → Sell | Citigroup |
| 12/3/2024 | $16.00 | Sell | Goldman |
| 8/30/2024 | $19.50 | Neutral | UBS |
| 1/29/2024 | $23.00 | Neutral | Citigroup |
| 1/22/2024 | $20.50 → $23.00 | Overweight → Equal-Weight | Morgan Stanley |
Impressive Adjusted EBITDA Margin Expansion and Cash Generation Full Year 2025 Guidance Reaffirmed Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and six-month period, which ended June 30, 2025 (second quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Second-Quarter 2025 Highlights 2Q25 Revenue increased 13.5% YoY to R$919.4 million. Revenue excluding acquisitions increased 8.5%, reaching R$879.0 million. 2
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today, its Board of Directors has approved a new share repurchase program. Under the share repurchase program, Afya may repurchase up to 4,000,000 of its outstanding Class A common shares, in the open market, based on prevailing market prices, or in privately negotiated transactions, beginning from August 15, 2025 until the earlier of the completion of the repurchase or December 31, 2026, depending upon market conditions. The share purchases may be made from time to time through open market transactions and are subject to marke
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announces the release of its 2024 Sustainability Report. The document, which presents Afya's trajectory throughout 2024, follows the Global Reporting Initiative (GRI) standards and is aligned with the Sustainable Development Goals (SDGs). It also reports specific indicators from the Sustainability Accounting Standards Board (SASB) and elements of the International Integrated Reporting Council (IIRC). The sustainability report contains some of the results of the fifth Greenhouse Gas (GHG) Emissions Inventory. Both of which have undergone
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
6-K - Afya Ltd (0001771007) (Filer)
Morgan Stanley upgraded Afya from Underweight to Overweight and set a new price target of $17.50
Citigroup upgraded Afya from Sell to Neutral and set a new price target of $14.00
Morgan Stanley downgraded Afya from Equal-Weight to Underweight and set a new price target of $17.00 from $19.00 previously
Afya Limited, or "Afya" (NASDAQ:AFYA) announced today that the resolutions set out in its Notice of Annual General Meeting dated June 9, 2025 was duly passed at its Annual General Meeting held today: (1) the approval and ratification of Afya's financial statements as of and for the fiscal year ended December 31, 2024; (2) the re-appointment of João Paulo Seibel de Faria as an independent director of the Company with immediate effect to hold office for a two year term; (3) the re-appointment of Vanessa Claro Lopes as an independent director of the Company with immediate effect to hold office for a two year term; (4) the re-appointment of Miguel Filisbino Pereira de Paula as an independent di
NOVA LIMA, Brazil and MINAS GERAIS, Brazil, Jan. 15, 2021 (GLOBE NEWSWIRE) -- Afya Limited, or Afya (Nasdaq: AFYA), today announces that its clinical decision software, WhiteBook, an app created by PEBMED, was ranked as one of the 10 Top Apps in Brazil by consumer spend in 2020 for the fifth year in a row. App Annie conducted the study, a website specialized in app analytics and app market data that combined data from iOS and Google Play that evaluates more than 8 million mobile app per year. In the top ten WhiteBook was among great apps such as Tinder, YouTube, Netflix, TikTok and others. Whitebook is a mobile and web application software that helps doctors and medical students to make
Impressive Adjusted EBITDA Margin Expansion and Cash Generation Full Year 2025 Guidance Reaffirmed Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three and six-month period, which ended June 30, 2025 (second quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). Second-Quarter 2025 Highlights 2Q25 Revenue increased 13.5% YoY to R$919.4 million. Revenue excluding acquisitions increased 8.5%, reaching R$879.0 million. 2
Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, announced today, its Board of Directors has approved a new share repurchase program. Under the share repurchase program, Afya may repurchase up to 4,000,000 of its outstanding Class A common shares, in the open market, based on prevailing market prices, or in privately negotiated transactions, beginning from August 15, 2025 until the earlier of the completion of the repurchase or December 31, 2026, depending upon market conditions. The share purchases may be made from time to time through open market transactions and are subject to marke
Impressive Adjusted EBITDA Margin Expansion and Cash Generation Full Year 2025 Guidance Reaffirmed Afya Limited (NASDAQ:AFYA, B3: A2FY34)) ("Afya" or the "Company"), the leading medical education group and medical practice solutions provider in Brazil, reported today its financial and operating results for the three-month period ended March 31, 2025 (first quarter 2025). Financial results are expressed in Brazilian Reais and are presented in accordance with International Financial Reporting Standards (IFRS). First Quarter 2025 Highlights 1Q25 Net Revenue increased 16.4% YoY to R$936.4 million. Net Revenue excluding acquisitions increased 10.9%, reaching R$891.5 million. 1Q25 Adjusted
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)
SC 13G/A - Afya Ltd (0001771007) (Subject)